Breaking News Instant updates and real-time market news.

2022-12-01 14:34:33 KMX CarMax $69.36 / -0.01 (-0.01%) 14:34 12/01/22 12/01 14:34 12/01/22 14:34	CarMax reaches settlement with 36 AGs to resolve 2014 vehicle recall inquiry CarMax has reached a settlement with the Attorneys General of 36 states to resolve a 2014 inquiry surrounding its advertising and sales practices related to vehicle recalls. Since 2014, CarMax has been disclosing vehicle specific recall information in our sales process and online advertising. The settlement terms are consistent with CarMax's longstanding practices. "CarMax led the industry in recall transparency by sharing vehicle specific recall information in-store and online to ensure our customers know about open recalls prior to purchase. In fact, as soon as NHTSA made available vehicle specific recall information in 2014, we began providing the information to customers nationwide and we continue to do so today. As CarMax is not authorized by manufacturers to complete recall repairs and close out recalls, we work hard to ensure our customers have the information they need to take action and have recalls repaired at a manufacturer-authorized facility," said Joe Wilson, Chief Operating Officer. Reference Link	22 Dec

2022-12-01 14:34:33

KMX

CarMax

$69.36 / -0.01 (-0.01%)

14:34

12/01/22

12/01

14:34

12/01/22

14:34

CarMax reaches settlement with 36 AGs to resolve 2014 vehicle recall inquiry

CarMax has reached a settlement with the Attorneys General of 36 states to resolve a 2014 inquiry surrounding its advertising and sales practices related to vehicle recalls. Since 2014, CarMax has been disclosing vehicle specific recall information in our sales process and online advertising. The settlement terms are consistent with CarMax's longstanding practices. "CarMax led the industry in recall transparency by sharing vehicle specific recall information in-store and online to ensure our customers know about open recalls prior to purchase. In fact, as soon as NHTSA made available vehicle specific recall information in 2014, we began providing the information to customers nationwide and we continue to do so today. As CarMax is not authorized by manufacturers to complete recall repairs and close out recalls, we work hard to ensure our customers have the information they need to take action and have recalls repaired at a manufacturer-authorized facility," said Joe Wilson, Chief Operating Officer. Reference Link

22
Dec

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Other EV startups may need to consider actions like Lucid, says Morgan Stanley » 08:22 03/29/23 03/29 08:22 03/29/23 08:22 LCID Lucid Group $7.56 / -0.58 (-7.13%) , RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) , LI Li Auto $24.77 / +1.58 (+6.81%) , NIO Nio $9.21 / +0.27 (+3.02%) , XPEV XPeng $10.25 / +0.55 (+5.67%) After Lucid Group… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 07:33 Today Lucid Group to cut workforce by about 18% as part of restructuring plan 03/28/23 Lucid Group down 6% to $7.64 following report of layoffs 03/27/23 Lucid recalls 2022-2023 Lucid Air vehicles for issue with electric motors 02/22/23 Lucid Group down 8% afterhours at $9.14 after Q4 results and 2023 outlook RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 02/28/23 Rivian Automotive down 6% following quarterly report 02/28/23 Rivian Automotive sees 50,000 vehicles produced in 2023 02/14/23 Greenlight buys Tenet, exits Intel in Q4 02/13/23 Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4 LI Li Auto $24.77 / +1.58 (+6.81%) 03/01/23 Li Auto delivers 16,620 vehicles in February 02/08/23 Li Auto launches Li L7, a five-seat flagship family SUV 02/01/23 Li Auto delivers 15,141 vehicles in January 01/02/23 Fly Intel: Top five weekend stock stories NIO Nio $9.21 / +0.27 (+3.02%) 03/22/23 Nio rise 3% to $9.52 after positive CFO comments on 2023 sales 03/01/23 Nio says achieved record-breaking quarterly delivery on Q4 02/01/23 Nio delivers 8,506 vehicles in January 01/24/23 NIO trading resumes XPEV XPeng $10.25 / +0.55 (+5.67%) 03/17/23 XPeng rises 10.8% 03/17/23 XPeng announces 5,218 vehicles delivered in January 03/10/23 XPeng laiuches P7i sports sedan in China 03/01/23 XPeng delivers 6,010 Smart EVs in February LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/02/23 Citi Lucid Group price target lowered to $11.50 from $12 at Citi 02/23/23 R.F. Lafferty Lucid Group price target lowered to $12 from $17 at R.F. Lafferty 02/23/23 Exane BNP Paribas Lucid Group downgraded to Neutral from Outperform at Exane BNP Paribas 02/23/23 Cantor Fitzgerald Lucid Group price target lowered to $13 from $18 at Cantor Fitzgerald RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/22/23 Morgan Stanley Rivian now trading just below cash value, says Morgan Stanley 03/21/23 Morgan Stanley EV price cuts 'not a fad, but a trend,' says Morgan Stanley 03/10/23 BofA Rivian Automotive resumed with Buy, reduced target at BofA 03/09/23 Mizuho Rivian Automotive price target lowered to $35 from $37 at Mizuho LI Li Auto $24.77 / +1.58 (+6.81%) 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley 03/20/23 Morgan Stanley Nio price target lowered to $12 from $16.10 at Morgan Stanley 03/03/23 HSBC Li Auto price target raised to $36 from $35 at HSBC NIO Nio $9.21 / +0.27 (+3.02%) 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley 03/20/23 Morgan Stanley Nio price target lowered to $12 from $16.10 at Morgan Stanley 03/02/23 Mizuho Nio price target lowered to $25 from $28 at Mizuho XPEV XPeng $10.25 / +0.55 (+5.67%) 03/24/23 Bernstein XPeng downgraded to Market Perform from Outperform at Bernstein 03/24/23 Bernstein XPeng downgraded to Market Perform from Outperform at Bernstein 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 02/22/23 Lucid Group reports Q4 EPS (28c), consensus (40c) 02/22/23 Notable companies reporting after market close 11/08/22 Lucid Group reports Q3 EPS (40c), consensus (31c) 11/08/22 Notable companies reporting after market close RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 02/28/23 Rivian Automotive reports Q4 adjusted EPS ($1.73), consensus ($1.94) 02/28/23 Notable companies reporting after market close 02/02/23 Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c 11/09/22 Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82) LI Li Auto $24.77 / +1.58 (+6.81%) 02/27/23 Li Auto reports Q4 EPS 4c, consensus 2c 12/09/22 Li Auto sees Q4 revenue $2.32B-$2.47B, consensus $2.55B 12/09/22 Li Auto reports Q3 EPS (18c), consensus (15c) NIO Nio $9.21 / +0.27 (+3.02%) 03/01/23 Nio reports Q4 EPS (44c) 11/10/22 Nio reports Q3 adjusted EPS (30c), consensus (16c) XPEV XPeng $10.25 / +0.55 (+5.67%) 03/17/23 XPeng sees Q1 revenue down 43.7%-46.3%, consensus $882.99M 03/17/23 XPeng reports Q4 adjusted EPS (37c), consensus (36c) 11/30/22 XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B 11/30/22 XPeng reports Q3 EPS (36c), consensus (36c) LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 Lucid Group to eliminate 18% of workforce, Insider reports 01/30/23 Fuzzy Panda short Lucid Group, calls buyout rumor 'fake news' 01/30/23 Fuzzy Panda says sell Lucid Group on 'fake' buyout rumor 01/27/23 Lucid Group spike attributed to takeout speculation by Betaville RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/13/23 Amazon, Rivian in discussions to drop exclusivity part of van deal, WSJ says 03/03/23 Rivian tells staff production of 62,000 EVs possible in 2023, Bloomberg says 03/03/23 Rivian tells staff production of 62,000 EVs possible this year, Bloomberg says 02/03/23 Rivian Automotive to expand lineup with development of e-bike, Bloomberg says LI Li Auto $24.77 / +1.58 (+6.81%) 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports 12/13/22 Geely's premium brand Zeekr confidentially files for U.S. IPO, Reuters says NIO Nio $9.21 / +0.27 (+3.02%) 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports 12/26/22 Nio CEO warns of sales challenges in first half of the year, Bloomberg reports 12/13/22 Geely's premium brand Zeekr confidentially files for U.S. IPO, Reuters says XPEV XPeng $10.25 / +0.55 (+5.67%) 01/17/23 XPeng follows Tesla with price cuts in China, Reuters reports 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 What You Missed On Wall Street On Tuesday 02/27/23 What You Missed This Week in EVs and Clean Energy 02/23/23 What You Missed On Wall Street On Thursday 02/23/23 What You Missed On Wall Street This Morning RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/20/23 What You Missed This Week in EVs and Clean Energy 03/13/23 What You Missed On Wall Street On Monday 03/13/23 What You Missed This Week in EVs and Clean Energy LI Li Auto $24.77 / +1.58 (+6.81%) 03/20/23 What You Missed This Week in EVs and Clean Energy 02/27/23 What You Missed On Wall Street On Monday 02/27/23 What You Missed On Wall Street This Morning 02/27/23 Fly Intel: Pre-market Movers NIO Nio $9.21 / +0.27 (+3.02%) 03/26/23 Opening Day: Singapore's Ohmyhome makes Nasdaq debut 03/20/23 What You Missed This Week in EVs and Clean Energy 03/18/23 Opening Day: China's Intchains, ICZOOM make U.S. debut 03/11/23 Opening Day: Atlas Energy raises $324M in 2023's second biggest IPO XPEV XPeng $10.25 / +0.55 (+5.67%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 03/20/23 What You Missed This Week in EVs and Clean Energy 04/24/23 Lucid Group Inc LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/21/23 Largest borrow rate increases among liquid names 02/28/23 Largest borrow rate increases among liquid names 02/27/23 Largest borrow rate increases among liquid names 02/22/23 Lucid Group options imply 13.9% move in share price post-earnings RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/08/23 Notable open interest changes for March 8th 03/07/23 Unusually active option classes on open March 7th 03/02/23 Rivian put buyer realizes 7% same-day gains 02/28/23 Rivian options imply 11.8% move in share price post-earnings LI Li Auto $24.77 / +1.58 (+6.81%) 02/27/23 Unusually active option classes on open February 27th 02/13/23 Li Auto call volume above normal and directionally bullish 02/13/23 Unusually active option classes on open February 13th 12/22/22 Li Auto call buyer realizes 39% same-day gains NIO Nio $9.21 / +0.27 (+3.02%) 03/13/23 NIO call volume above normal and directionally bullish 03/06/23 NIO call volume above normal and directionally bullish 03/01/23 Unusually active option classes on open March 1st 02/06/23 NIO call volume above normal and directionally bullish XPEV XPeng $10.25 / +0.55 (+5.67%) 03/21/23 Unusually active option classes on open March 21st 03/17/23 Unusually active option classes on open March 17th 03/09/23 Largest borrow rate increases among liquid names 01/30/23 XPeng call volume above normal and directionally bullish
Recommendations	Lovesac price target raised to $36 from $32 at Roth MKM » 08:21 03/29/23 03/29 08:21 03/29/23 08:21 LOVE Lovesac $27.01 / +3.055 (+12.75%) Roth MKM analyst Matt… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LOVE Lovesac $27.01 / +3.055 (+12.75%) 01/04/23 Lovesac director buys $847K in common stock 12/07/22 Lovesac reports Q3 SSS up 8.9% 11/03/22 Lovesac appoints John Legg as CSCO LOVE Lovesac $27.01 / +3.055 (+12.75%) 12/08/22 DA Davidson Lovesac price target lowered to $64 from $97 at DA Davidson 12/08/22 Craig-Hallum Lovesac price target lowered to $60 from $100 at Craig-Hallum 12/08/22 Canaccord Lovesac price target lowered to $50 from $55 at Canaccord 09/09/22 DA Davidson Lovesac price target lowered to $97 from $124 at DA Davidson LOVE Lovesac $27.01 / +3.055 (+12.75%) 03/28/23 Lovesac sees 2024 EPS $1.83-$2.24, consensus $2.10 03/28/23 Lovesac sees Q1 EPS (36c)-(37c), consensus (6c) 03/28/23 Lovesac reports Q4 EPS $1.74, consensus $1.72 12/07/22 Lovesac reports Q3 EPS (55c), consensus (76c) LOVE Lovesac $27.01 / +3.055 (+12.75%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/30/23 Lovesac 04/11/23 Lovesac LOVE Lovesac $27.01 / +3.055 (+12.75%) 01/06/23 Largest borrow rate increases among liquid names
Hot Stocks	Achieve Life says last subject's last visit complete for Phase 3 ORCA-3 trial » 08:20 03/29/23 03/29 08:20 03/29/23 08:20 ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) Achieve Life Sciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 03/17/23 Achieve Life Sciences announces grant of new hire inducement award 03/08/23 Achieve Life announce last subject last visit complete in Phase 2 ORCA-V1 trial 03/03/23 Achieve Life Sciences presents Phase 3 ORCA-2 trial data 02/07/23 Achieve Life Sciences doses last subject in Phase 2 ORCA-V1 trial ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 11/16/22 Maxim Achieve Life Sciences price target lowered to $8 from $21 at Maxim 11/15/22 Oppenheimer Achieve Life Sciences price target lowered to $20 from $27 at Oppenheimer 04/27/22 Oppenheimer Achieve Life Sciences price target raised to $27 from $23 at Oppenheimer ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 03/16/23 Achieve Life Sciences reports Q4 EPS (83c), consensus (83c) 11/14/22 Achieve Life Sciences reports Q3 EPS ($1.35), consensus ($1.13) ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 01/12/23 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	Proterra announces South Carolina Department of Education to deploy 160 TBB » 08:20 03/29/23 03/29 08:20 03/29/23 08:20 PTRA Proterra $1.50 / +0.05 (+3.45%) The South Carolina… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PTRA Proterra $1.50 / +0.05 (+3.45%) 03/24/23 Proterra congratulates LG Energy Solution on Arizona battery manufacturing 03/20/23 Proterra reaches binding letter of intent with Cowen convertible note holders 02/23/23 Proterra, Thomas Built Buses reach major milestone for electric school buses 02/13/23 Proterra appoints Julian Soell as COO, Chris Bailey as Chief Business Officer PTRA Proterra $1.50 / +0.05 (+3.45%) 03/17/23 DA Davidson Proterra price target lowered to $5 from $10 at DA Davidson 03/16/23 BTIG Proterra price target lowered to $6 from $7 at BTIG 10/17/22 BTIG Proterra initiated with a Buy at BTIG 09/28/22 Truist Truist starts Proterra at Buy, positive on commercial EV battery niche PTRA Proterra $1.50 / +0.05 (+3.45%) 03/15/23 Proterra sees FY23 revenue $450M-$500M, consensus $533.8M 03/15/23 Proterra reports Q4 EPS (50c), consensus (25c) PTRA Proterra $1.50 / +0.05 (+3.45%) 03/16/23 What You Missed On Wall Street On Thursday 03/16/23 What You Missed On Wall Street This Morning 10/17/22 What You Missed This Week in EVs and Clean Energy PTRA Proterra $1.50 / +0.05 (+3.45%) 03/08/23 Proterra options imply 8.3% move in share price post-earnings 03/03/23 Unusually active option classes on open March 3rd
Hot Stocks	BioCardia sees cash runway into 3Q23 » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Net cash used in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 08:19 Today BioCardia reports 2022 EPS (67c) vs. (75c) last year 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Earnings	BioCardia reports 2022 EPS (67c) vs. (75c) last year » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Reports 2022 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Hot Stocks	Olink technology enables further development of South African research » 08:18 03/29/23 03/29 08:18 03/29/23 08:18 OLK Olink $19.83 / -1.8 (-8.32%) Olink announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly OLK Olink $19.83 / -1.8 (-8.32%) 03/21/23 Olink announces Bruno Rossi joins the company as Chief Commercial Officer 03/06/23 Olink implementation of technology at NUS Medicine 02/28/23 Olink establishes agreement with RGC to scale proteomics efforts 11/03/22 Olink announces 1,000 peer-reviewed articles citing use of PEA technology OLK Olink $19.83 / -1.8 (-8.32%) 01/05/23 Scotiabank Olink initiated with an Outperform at Scotiabank 01/04/23 Scotiabank Olink initiated with an Outperform at Scotiabank 12/14/22 Canaccord Olink initiated with a Buy at Canaccord OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Olink sees FY23 revenue $192M-$200M, consensus $193.48M 02/21/23 Olink reports Q4 EPS 5c, consensus 1c 01/09/23 Olink sees FY23 revenue $192M-$200M, consensus $199.3M 01/09/23 Olink narrows FY22 revenue view to $139.4M-$139.8M from $138M-142M 19 Jan OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Fly Intel: Pre-market Movers 01/18/23 Fly Intel: After-Hours Movers
Hot Stocks	Verses, SimWell partner to enhance digital twin stimulations with KOSMOS » 08:17 03/29/23 03/29 08:17 03/29/23 08:17 VRSSF Verses Technologies / + VERSES Technologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News VRSSF Verses Technologies / + 03/22/23 Verses Technologies closes second tranche of convertible debenture financing 03/01/23 Verses closes $5M tranche, announces upsize of convertible debenture financing 02/27/23 Verses Technologies announces convertible debenture financing up to C$5M 02/23/23 Verses Technologies announces General Intelligent Agent, codenamed GIA
Hot Stocks	Crispr Therapeutics announces departure of board member » 08:16 03/29/23 03/29 08:16 03/29/23 08:16 CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) CRISPR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact 03/13/23 Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed 12/27/22 Cathie Wood's ARK Investment bought 10.8K shares of Crispr Therapeutics today 12/19/22 Crispr Therapeutics appoints Harding as SVP, Head of Business Development CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/21/23 Bernstein Crispr Therapeutics initiated with a Market Perform at Bernstein 03/18/23 Citi Crispr Therapeutics price target lowered to $55 from $63 at Citi 03/17/23 Bryan Garnier Crispr Therapeutics initiated with a Buy at Bryan Garnier 03/06/23 Baird Baird starts Crispr at Neutral with strong launch priced in CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y 04/03/23 The Future of Oncology Virtual Symposium CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/21/23 Crispr Therapeutics options imply 4.4% move in share price post-earnings 02/14/23 Crispr Therapeutics options imply 4.9% move in share price post-earnings 01/05/23 Crispr Therapeutics call volume above normal and directionally bullish
Hot Stocks	G Medical Innovations enters into agreement with AdventHealth Central Florida » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) G Medical Innovations… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) 03/27/23 G Medical Innovations, MiCare Path announce joint collaboration 02/13/23 G Medical Innovations receives patent from USPTO for vital sign sensors 01/30/23 G Medical Innovations granted patent by USPTO for vital signs sensors 12/05/22 G Medical Innovations receives two U.S. patents for monitoring products

Hot Stocks	Caribou initiates dose expansion portion of CB-010 ANTLER Phase 1 trial » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 08:12 Today Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Hot Stocks	First Solar announces facility in India awarded financial incentives » 08:13 03/29/23 03/29 08:13 03/29/23 08:13 FSLR First Solar $210.01 / +0.08 (+0.04%) First Solar announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options FSLR First Solar $210.01 / +0.08 (+0.04%) 03/01/23 Origis Energy enters agreeent with First Solar for 2 GW of modules 02/28/23 First Solar announces Lightsource bp places multi-year order for 4 GW 01/12/23 First Solar completes sale of 141 MW Luz del Norte power plant to Toesca 12/19/22 First Solar to replace Fortune Brands in S&P 500 at open on 12/19 FSLR First Solar $210.01 / +0.08 (+0.04%) 03/23/23 Barclays First Solar price target raised to $230 from $162 at Barclays 03/15/23 Credit Suisse First Solar price target raised to $163 from $152 at Credit Suisse 03/14/23 Argus First Solar price target raised to $261 from $176 at Argus 03/09/23 Citi First Solar transferred with Neutral rating at Citi FSLR First Solar $210.01 / +0.08 (+0.04%) 02/28/23 First Solar sees FY23 EPS $7.00-$8.00, consensus $4.77 02/28/23 First Solar reports Q4 EPS (7c), consensus (15c) 02/28/23 Notable companies reporting after market close 10/27/22 First Solar reports Q3 EPS (46c), consensus (27c) FSLR First Solar $210.01 / +0.08 (+0.04%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports FSLR First Solar $210.01 / +0.08 (+0.04%) 03/06/23 What You Missed This Week in EVs and Clean Energy 03/03/23 What You Missed On Wall Street On Friday 03/03/23 What You Missed On Wall Street This Morning 02/28/23 Fly Intel: After-Hours Movers FSLR First Solar $210.01 / +0.08 (+0.04%) 03/08/23 Unusually active option classes on open March 8th 03/06/23 Early notable gainers among liquid option names on March 6th 03/03/23 Early notable gainers among liquid option names on March 3rd 03/01/23 Early notable gainers among liquid option names on March 1st
Hot Stocks	Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Recommendations	Viking Therapeutics price target raised to $25 from $15 at Maxim » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735 03/28/23 Viking Therapeutics jumps 32% to $12.06 after Phase 1 VK2735 trial results 03/28/23 Viking Therapeutics announces results from Phase 1 trial of VK2735 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 06:15 Today Raymond James Viking Therapeutics price target raised to $35 from $12 at Raymond James 03/28/23 BTIG Viking Therapeutics price target raised to $31 from $20 at BTIG 03/28/23 Oppenheimer Viking Therapeutics price target raised to $30 from $20 at Oppenheimer 03/28/23 Stifel Stifel reiterates Buy on Viking Therapeutics, raises price target to $25 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish
Hot Stocks	Enphase Energy launches new IQ8 microinverters in France, the Netherlands » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 ENPH Enphase Energy $193.50 / -2.28 (-1.16%) Enphase Energy announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/20/23 Enphase Energy expands IQ8 microinverter deployments in Virginia 03/13/23 Enphase Energy expands IQ8 microinveter deployments in Utah 03/06/23 Enphase Energy expands IQ8 microinverter deployments in Illinois 02/26/23 Fly Intel: Top five weekend stock stories ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/22/23 Susquehanna Enphase upgraded to Positive on recent pullback at Susquehanna 03/22/23 Susquehanna Enphase Energy upgraded to Positive from Neutral at Susquehanna 03/20/23 Raymond James Enphase Energy upgraded to Outperform from Market Perform at Raymond James 03/09/23 Citi Enphase Energy transferred with Buy rating at Citi ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/07/23 Enphase Energy sees Q1 revenue $700M-$740M, consensus $690.46M 02/07/23 Enphase Energy reports Q4 EPS $1.51, consensus $1.24 02/07/23 Notable companies reporting after market close 10/25/22 Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/25/23 Corning, Enphase among key U.S. Clean Energy players, Barron's says ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/23/23 Early notable gainers among liquid option names on March 23rd 03/20/23 Early notable gainers among liquid option names on March 20th 03/06/23 Early notable gainers among liquid option names on March 6th 02/27/23 Early notable gainers among liquid option names on February 27th
Hot Stocks	Akari announces Poland, U.K. approve new manufacturing process for nomacopan » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AKTX Akari Therapeutics / + Akari Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research AKTX Akari Therapeutics / + 02/21/23 Akari Therapeutics presents case study from Phase 3 Part A trial of nomacopan 02/15/23 Akari announces pre-clinical development progress toward IND for GA treatment 02/13/23 Akari Therapeutics announces acceleration of Phase 3 trial of nomacopan 11/10/22 Akari Therapeutics announces FDA granted RPDD to nomacopan AKTX Akari Therapeutics / + 12/05/22 H.C. Wainwright Akari Therapeutics initiated with a Buy at H.C. Wainwright 11/01/22 Alliance Global Partners Akari Therapeutics initiated with a Buy at Alliance Global Partners
Upgrade	Anhui Conch Cement upgraded to Neutral from Sell at Goldman Sachs » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) 11/15/22 HSBC Anhui Conch Cement upgraded to Buy from Hold at HSBC 08/28/22 Goldman Sachs Anhui Conch Cement downgraded to Sell from Neutral at Goldman Sachs
Hot Stocks	Kala Pharmaceuticals appoints Francis Mah as chief medical advisor » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) Kala Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/27/23 Kala announces safety update from Cohort 1 of CHASE Phase 2b trial 02/14/23 Kala recruiting for study of KPI-012 in participants with PCED 01/19/23 Kala Pharmaceuticals falls 10% to $15.90 after equity offering 12/30/22 Kala Pharmaceuticals trading resumes KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/06/23 H.C. Wainwright Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright 12/29/22 Wedbush IND acceptance sets up Kala for execution year in 2023, says Wedbush 11/09/22 Wedbush Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush 05/24/22 H.C. Wainwright Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/03/23 Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year 11/08/22 Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 01/19/23 Fly Intel: After-Hours Movers 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 Fly Intel: After-Hours Movers 04/24/23 Kala Pharmaceuticals, Inc.
Hot Stocks	NV5 awarded $11M essential infrastructure projects in California, New Mexico » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 NVEE NV5 Global $100.90 / +0.02 (+0.02%) NV5 Global announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVEE NV5 Global $100.90 / +0.02 (+0.02%) 03/13/23 NV5 Global announces $11M in engineering, planning awards 03/06/23 NV5 Global announces Axim Geospatial awarded $9M in national security contracts 03/02/23 NV5 Global acquires Gaudet Associates 02/23/23 NV5 Global announces acquisition of Axim Geospatial NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/24/23 Baird NV5 Global price target lowered to $130 from $150 at Baird 08/05/22 Lake Street NV5 Global price target raised to $175 from $136 at Lake Street NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/23/23 NV5 Global reports Q4 EPS $1.21 , consensus $1.57 11/03/22 NV5 Global reports Q3 adjusted EPS $1.50, consensus $1.45
Hot Stocks	DoubleDown announces results of 2023 Annual General Meeting » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 DDI DoubleDown $8.09 / +0.08 (+1.00%) DoubleDown Interactive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research DDI DoubleDown $8.09 / +0.08 (+1.00%) 01/11/23 DoubleDown to acquire i-Gaming company SuprNation for $35M 12/28/22 DoubleDown announces results of EGM held on December 28 DDI DoubleDown $8.09 / +0.08 (+1.00%) 09/15/22 Macquarie DoubleDown initiated with an Outperform at Macquarie 07/11/22 B. Riley Investors have overlooked DoubleDown, says B. Riley 06/28/22 B. Riley DoubleDown price target lowered to $20 from $30 at B. Riley

Initiation	Engie Brasil initiated with an Outperform at Scotiabank » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) Scotiabank analyst Renato… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) 03/07/23 UBS Engie Brasil upgraded to Buy from Neutral at UBS 01/10/23 JPMorgan Engie Brasil upgraded to Overweight from Neutral at JPMorgan 10/14/22 JPMorgan Engie Brasil upgraded to Neutral from Underweight at JPMorgan 08/08/22 JPMorgan Engie Brasil downgraded to Underweight from Neutral at JPMorgan
Recommendations	LuxUrban Hotels price target raised to $7 from $6 at Maxim » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 02/16/23 LuxUrban Hotels announces preferred U.S.hotel partnership with NusaTrip 02/08/23 LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms 12/02/22 LuxUrban Hotels names Jimmie Chatmon COO 12/01/22 LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 12/12/22 Maxim LuxUrban Hotels initiated with a Buy at Maxim LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 01/18/23 LuxUrban Hotels affirms FY22 net rental revenue and EBITDA guidance
Hot Stocks	Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) Harmony Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' 01/09/23 Novavax names John Jacobs as new CEO, succeeding Stanley Erck 01/06/23 Harmony Biosciences CEO John Jacobs stepping down 11/15/22 Harmony Biosciences director sells $9.12M in common stock HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Mizuho Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 03/28/23 Raymond James Raymond James says buy Harmony on weakness after 'low quality' short report 02/22/23 Mizuho Harmony Biosciences price target lowered to $60 from $70 at Mizuho 01/04/23 Piper Sandler Harmony Biosciences price target raised to $70 from $62 at Piper Sandler HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 02/21/23 Harmony Biosciences reports Q4 non-GAAP EPS $1.01, consensus 58c 11/01/22 Harmony Biosciences reports Q3 non-GAAP EPS 95c vs 41c last year HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Scorpion: Filing Citizen's Petition to request withdrawal of Harmony drug 03/28/23 Scorpion Capital issues investigative report on Harmony Biosciences HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/28/23 Harmony plunges as Scorpion seeks FDA withdrawal of Wakix approval 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Rapt Therapeutics announces initiation of Phase 2a trial of RPT193 » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) RAPT Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/10/23 Rapt Therapeutics says $2M of cash held at Silicon Valley Bank 12/08/22 Rapt Therapeutics reports Phase 1/2 results of FLX475 in advanced cancer 11/17/22 Rapt Therapeutics falls 7% to $19.70 after $75M common stock offering RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/15/23 Capital One Rapt outlook 'remains steady' despite shift in timeline, says Capital One 03/15/23 Cantor Fitzgerald Rapt Therapeutics price target lowered to $40 from $44 at Cantor Fitzgerald 03/15/23 H.C. Wainwright Rapt Therapeutics price target lowered to $43 from $50 at H.C. Wainwright 01/04/23 Guggenheim Rapt Therapeutics initiated with a Buy at Guggenheim RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/14/23 Rapt Therapeutics reports Q4 EPS (64c), consensus (66c) 11/10/22 Rapt Therapeutics reports Q3 EPS (63c), consensus (67c) 18 Nov RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/16/23 Biotech Alert: Searches spiking for these stocks today 11/17/22 Fly Intel: After-Hours Movers
Hot Stocks	Pacira announces FDA clearance of sNDA for EXPAREL label » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PCRX Pacira $39.93 / -0.15 (-0.37%) Pacira BioSciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PCRX Pacira $39.93 / -0.15 (-0.37%) 03/27/23 Court upholds decision to dismiss Pacira lawsuit against ASA 03/22/23 Pacira announces Yvonne Greenstreet to retire from Board 02/28/23 Pacira sees 2023 EXPAREL net sales $570M-$580M 02/23/23 Pacira, LPGA partner to raise awareness of non-opioid pain management solutions PCRX Pacira $39.93 / -0.15 (-0.37%) 03/03/23 Barclays Pacira price target lowered to $80 from $90 at Barclays 03/01/23 H.C. Wainwright Pacira price target raised to $71 from $69 at H.C. Wainwright 02/10/23 H.C. Wainwright Pacira price target lowered to $69 from $76 at H.C. Wainwright 01/31/23 Wedbush Pacira assumed with an Outperform at Wedbush PCRX Pacira $39.93 / -0.15 (-0.37%) 02/28/23 Pacira reports Q4 adjusted EPS 80c, consensus 83c 01/05/23 Pacira sees FY22 EPS 'at least' $2.50, consensus $2.77 11/03/22 Pacira reports Q3 adjusted EPS 64c, consensus 76c 10/13/22 Pacira reports preliminary Q3 revenue $167.5M, consensus $172.72M

Events

Earnings calls, analyst events, roadshows and more

MINM
Today at 08:30

Minim - MINM Conference Calls
BLUE
Today at 08:30

Bluebird Bio - BLUE Conference Calls
BTMD
Today at 08:30

Biote - BTMD Conference Calls
GLYC
Today at 08:30

GlycoMimetics - GLYC Conference Calls
RDW
Today at 09:00

Redwire - RDW Conference Calls
BOSC
Today at 09:00

BOS Better Online Solutions - BOSC Conference Calls
IBEX
Today at 09:00

Ibex - IBEX Conference Calls
UNF
Today at 09:00

UniFirst - UNF Conference Calls
CLH
Today at 09:00

Clean Harbors Firm Sponsored Meetings

Virtual Meeting
PAYX
Today at 09:30

Paychex - PAYX Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	YGF X YGF YanGuFang IPO Managers: EF Hutton Priced at: $4.00 2M Shares ZJYL X ZJYL Jin Medical IPO Managers: Prime Number Priced at: $8.00 1M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	BMEA X BMEA Biomea Fusion Secondary Managers: JPMorgan & Citi, Oppenheimer, Barclays $30.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	SYT X SYT Syla Technologies IPO Managers: Boustead $8.00 1.875M Shares
Fri	No deals

View All Syndicate Announcements »

CarMax reaches settlement with 36 AGs to resolve 2014 vehicle recall inquiry

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access